Trial reportNephrology (Carlton, Vic.)2026
Efficacy of Reticulocyte Haemoglobin Equivalent-Guided Versus Transferrin Saturation-Guided Iron Supplement Protocol in Haemodialysis Patients: A Multicenter Cluster Randomized Controlled Trial.
Trial report in Nephrology (Carlton, Vic.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIron deficiency is common in patients receiving haemodialysis and contributes to adverse outcomes. Conventional iron biomarkers, including ferritin and transferrin saturation (TSAT), have limitations and may be less accessible in some settings. Reticulocyte haemoglobin equivalent (RET-He) is a lower-cost, potentially more accessible marker for detection of iron deficiency. This study evaluated whether RET-He-guided intravenous iron supplementation is non-inferior to TSAT-guided supplementation in haemodialysis patients.
methodsIn this randomized non-inferiority trial, 160 haemodialysis patients were randomized to a TSAT-guided group (n = 79) or RET-He-guided group (n = 81). Intravenous iron was administered in both groups according to prespecified protocols. The primary outcome was the erythropoietin resistance index (ERI) at 3 and 6 months. RET-He guidance was considered non-inferior if the upper bound of the 95% confidence interval (CI) for the between-group mean difference was ≤ 160 units/week/g/dL. Secondary outcomes included all-cause mortality, hospitalization, cardiovascular events, blood transfusion, and infection.
resultsBaseline characteristics were comparable between groups. RET-He-guided supplementation was non-inferior to TSAT-guided supplementation for ERI at 3 months (mean difference, -35.92; 95% CI, -155.60 to 90.29; p = 0.001 for non-inferiority) and 6 months (mean difference, -39.68; 95% CI, -187.01 to 107.64; p = 0.004 for non-inferiority). The RET-He group received significantly lower cumulative intravenous iron doses. Secondary outcomes did not differ significantly, although the trial was not powered for these clinical outcomes.
conclusionRET-He-guided intravenous iron supplementation was non-inferior to TSAT-guided supplementation for reducing ERI over 6 months. Use of RET-He may offer a lower-cost and more accessible strategy for anaemia management in haemodialysis patients, particularly in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.